Advances in kidney transplant immunosuppression: Emerging biologics

Authors


Abstract

There remains a need in solid-organ transplantation for an immunosuppressive agent with a novel mechanism of action and fewer adverse consequences to replace current immunosuppressive drugs and improve long-term patient and graft survival. There are several agents on the horizon, both small molecules and biologics, offering this promise along with ease and consistency of long-term administration. We discuss three biologic agents currently in advanced stages of clinical trials in kidney transplantation.

Ancillary